Cover Image

PHREND®-A Real-World Data-Driven Tool Supporting Clinical Decisions to Optimize Treatment in Relapsing-Remitting Multiple Sclerosis

BackgroundWith increasing availability of disease-modifying therapies (DMTs), treatment decisions in relapsing-remitting multiple sclerosis (RRMS) have become complex. Data-driven algorithms based on real-world outcomes may help clinicians optimize control of disease activity in routine praxis.Objec...

Full description

Saved in:

Bibliographic Details
Main Authors:	Stefan Braune (Author), Elisabeth Stuehler (Author), Yanic Heer (Author), Philip van Hoevell (Author), Arnfin Bergmann (Author), NeuroTransData Study Group (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Subtypes of relapsing-remitting multiple sclerosis identified by network analysis
by: Quentin Howlett-Prieto, et al.
Published: (2023)

The condition of the cardiovascular system in patients with relapsing-remitting multiple sclerosis
by: O. A. Traktirskaya, et al.
Published: (2019)

A review of treatment of relapsing-remitting type of multiple sclerosis (RRMS)
by: Arkadiusz Bydliński, et al.
Published: (2024)

BRAIN AND LESION VOLUMES CORRELATE WITH EDSS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS.
by: Ivan Dimitrov, et al.
Published: (2015)

Intensive Circuit Class Therapy in Patients with Relapsing-Remitting Multiple Sclerosis
by: Jan Kocica, et al.
Published: (2022)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
by: Cocco E, et al.
Published: (2015)

Alemtuzumab: evidence for its potential in relapsing–remitting multiple sclerosis
by: Brown JWL, et al.
Published: (2013)

Relapsing-remitting multiple sclerosis arising in a patient with atopic dermatitis on dupilumab
by: Leah Laageide, MD, et al.
Published: (2021)

Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada
by: Virender Bhan, et al.
Published: (2023)

Comparing the Safety and Efficacy of Ziferon and Betaferon in Patients With Remitting-Relapsing Multiple Sclerosis
by: Mohammad Reza Gheini, et al.
Published: (2019)

Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
by: Guarnera C, et al.
Published: (2017)

The application of Kubler-Ross model in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis
by: Giorgia Teresa Maniscalco, et al.
Published: (2019)

Ocrelizumab-induced vulvovaginal pyoderma gangrenosum in a patient with relapsing-remitting multiple sclerosis
by: Annika Klumpp, MD, et al.
Published: (2022)

Effectiveness of comprehensive neurorehabilitation treatment on the cognitive function of patients with relapsing-remitting multiple sclerosis
by: Làzaro Aurelio Vàzquez Gòmez, et al.
Published: (2022)

Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
by: Làzaro Aurelio Vàzquez Gòmez, et al.
Published: (2022)

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
by: Mehdi Rezaee, et al.
Published: (2022)

Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
by: Guarnera C, et al.
Published: (2017)

Medication Adherence and Healthcare Utilization in Relapsing-Remitting Multiple Sclerosis Patients Using Teriflunomide
by: Greene N, et al.
Published: (2022)

Review of daclizumab and its therapeutic potential in the treatment of relapsing–remitting multiple sclerosis
by: Reardon J, et al.
Published: (2013)

Advances in the treatment of relapsing–remitting multiple sclerosis – critical appraisal of fingolimod
by: Gasperini C, et al.
Published: (2013)

Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis
by: Kira Groen, et al.
Published: (2018)

Diagnostic Dilemma: An Atypical Case of Astrocytoma in a Patient with Relapsing-Remitting Multiple Sclerosis
by: Chantal Kahovec, et al.
Published: (2021)

Cost-effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain
by: Ricardo Ginestal, et al.
Published: (2023)

Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis
by: Saharat Aungsumart, et al.
Published: (2023)

Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
by: Rozita Doosti, et al.
Published: (2021)

Quality of life in relapsing-remitting multiple sclerosis patients receiving CinnoVex compared with Avonex
by: Nahid Hatam, et al.
Published: (2016)

IL-18 PROMOTER POLYMORPHISM AND IL-18 SERUM LEVELS IN ASSOCIATION WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
by: Boncho Grigorov, et al.
Published: (2020)

Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
by: Mansour A. Alharbi, et al.
Published: (2023)

Investigating the Relationship Between Selective Attention and Cognitive Flexibility With Balance in Patients With Relapsing-Remitting Multiple Sclerosis
by: Vali Shiri, et al.
Published: (2018)

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis
by: Martin Vališ, et al.
Published: (2023)

Comparison some of the syntactic skills in Relapsing Remitting Multiple sclerosis and normal adults resident in Esfahan Province
by: Sedigheh Jamalpour, et al.
Published: (2013)

The Relationship Between Balance and Activities of Daily Living With the Quality of Life of Patients With Relapsing-Remitting Multiple Sclerosis
by: Mansour Noori, et al.
Published: (2019)

Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis
by: Ruggieri S, et al.
Published: (2014)

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
by: Gianluca Furneri, et al.
Published: (2019)

Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
by: Iciar Martínez-López, et al.
Published: (2020)

Cost-utility analysis of interferon beta-1a (Avonex and Cinnovex) for relapsing remitting multiple sclerosis
by: Rahil Sadat Shahtaheri, et al.
Published: (2018)

Impact of Body Mass Index on the Age of Relapsing-Remitting Multiple Sclerosis Onset: A Retrospective Study
by: Vasileios Siokas, et al.
Published: (2021)

Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies
by: Anna Bizoń, et al.
Published: (2022)

A Pediatric Case of Relapsing-Remitting Multiple Sclerosis Onset following Varicella Zoster Ophthalmicus with Optic Neuritis
by: Naoko Shiba, et al.
Published: (2018)

Exploring the Relationship between Antioxidant Enzymes, Oxidative Stress Markers, and Clinical Profile in Relapsing-Remitting Multiple Sclerosis
by: Anna Bizoń, et al.
Published: (2023)